Vaccines to Treat Substance Use Disorders: Current Status and Future Directions.
Tangsheng LuXue LiWei ZhengChenyan KuangBingyi WuXiaoxing LiuYanxue XueJie ShiLin LuYing HanPublished in: Pharmaceutics (2024)
Addiction, particularly in relation to psychostimulants and opioids, persists as a global health crisis with profound social and economic ramifications. Traditional interventions, including medications and behavioral therapies, often encounter limited success due to the chronic and relapsing nature of addictive disorders. Consequently, there is significant interest in the development of innovative therapeutics to counteract the effects of abused substances. In recent years, vaccines have emerged as a novel and promising strategy to tackle addiction. Anti-drug vaccines are designed to stimulate the immune system to produce antibodies that bind to addictive compounds, such as nicotine, cocaine, morphine, methamphetamine, and heroin. These antibodies effectively neutralize the target molecules, preventing them from reaching the brain and eliciting their rewarding effects. By obstructing the rewarding sensations associated with substance use, vaccines aim to reduce cravings and the motivation to engage in drug use. Although anti-drug vaccines hold significant potential, challenges remain in their development and implementation. The reversibility of vaccination and the potential for combining vaccines with other addiction treatments offer promise for improving addiction outcomes. This review provides an overview of anti-drug vaccines, their mechanisms of action, and their potential impact on treatment for substance use disorders. Furthermore, this review summarizes recent advancements in vaccine development for each specific drug, offering insights for the development of more effective and personalized treatments capable of addressing the distinct challenges posed by various abused substances.
Keyphrases
- global health
- healthcare
- multiple sclerosis
- primary care
- emergency department
- rheumatoid arthritis
- physical activity
- chronic pain
- drinking water
- adverse drug
- type diabetes
- small molecule
- metabolic syndrome
- risk assessment
- climate change
- systemic lupus erythematosus
- intellectual disability
- white matter
- machine learning
- pain management
- combination therapy
- quality improvement
- cerebral ischemia
- life cycle